Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 5, 2024British Journal of HaematologyOpen Access

Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime

View Full Paper
Ask AI
Bookmark
Share

Authors

JBJoshua BomsztykSRSriram RavichandranJKJahanzaib Khwaja

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bomsztyk et al. (2024) studied this question.

synapsesocial.com/papers/68e660c7b6db6435875ee60dhttps://doi.org/10.1111/bjh.19529
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Response matters in <scp>light chain</scp> amyloidosis, whatever it takes2024
  2. 2Effectiveness of second-line therapies following upfront daratumumab plus bortezomib, cyclophosphamide and dexamethasone: A new benchmark2025
  3. 3Daratumumab Monotherapy versus Bortezomib-Based Regimens in frail patients with Biopsy-Proven Renal AL Amyloidosis2026
  4. 4Daratumumab plus bortezomib and dexamethasone (Dara‐ <scp>VD</scp> ) in newly diagnosed Mayo 2004 stage <scp>IIIA</scp> and <scp>IIIB</scp> light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study2026
  5. 5A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide2025 · 2 citations